Trial · NCT03030612
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 30 of 30
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Phase 1 and Phase 2: Number of Participants with 30 Day and 60 Day Mortality | 30 and/or 60 days after the first administration | Number of participants with 30 Day and 60 Day Mortality will be reported. |
| Secondary | Phase 1 and Phase 2: Number of Participants Achieving Transfusion Independence (TI) | Up to 3.6 years | Number of participants reaching greater than or equal to (\>=) 8 consecutive weeks without red blood cell (RBC-TI) and/or platelet (PLT-TI) transfusion. The first day of the \>=8-week period with no transfusions is noted as the time at which participants first achieved TI. |
| Secondary | Phase 1 and Phase 2: Time to Transfusion Independence | Up to 3.6 years | Time until TI for RBC and/or PLT will be measured from the date of entry into a study to the first day of the 8-weeks period with no transfusions. |
| Secondary | Phase 1 and Phase 2: Duration of Transfusion Independence | Up to 3.6 years | Time between the last transfusion before the start of the TI period and the first transfusion after the start of the TI period, which occurred \>=8 weeks later. |
| Secondary | Phase 1 and Phase 2: Time to Neutrophil Recovery | Up to 3.6 years | Time to neutrophil recovery will be calculated from number of days from Day 1 of commencing study treatment to first day neutrophils 0.5 \* 10\^9 per liter or 1.0 \* 10\^9 per liter. |
| Secondary | Phase 1 and Phase 2: Time to Platelet Recovery | Up to 3.6 years | Time to platelet recovery will be calculated from number of days from day 1 of commencing study treatment to first day neutrophils 50 \* 10\^9 per liter or 100 \* 10\^9 per liter. |
| Secondary | Biomarker Assessment of ARGX-110 | Up to 3.6 years | Biomarkers including CD70 and CD27 assessment will be performed on bone marrow aspirates and/or whole blood. |
| Secondary | Phase 1: Levels of T, B and NK Cells | Up to 3.6 years | Levels of T, B and NK cells will be reported by immunophenotyping (performed by flow cytometry or mass cytometry). . |
| Secondary | Phase 1: Levels of B Cells | Up to 3.6 years | Levels of B cells will be reported. |
| Secondary | Phase 1: Levels of NK Cells | Up to 3.6 years | Levels of NK cells will be reported. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03030612/registered?page=2